qfx

Block, in its boundless experimentation, has begun to dabble in the arcane art of blockchain technology. A new offering, launched with the subtlety of a brass band, purports to demonstrate a ‘clear use case’ for the world’s leading cryptocurrency. One suspects the clarity is somewhat… illusory. Still, investors, those eager souls, should pay attention. Though what they might actually do with that attention is anyone’s guess.

CVS Health, a chain of pharmacies so ubiquitous it’s practically woven into the fabric of American life, operates over 9,000 locations. This isn’t merely a matter of retail expansion; it’s a subtle form of territorial dominance. They’ve been dispensing remedies and dubious snacks for decades, accumulating a level of community trust that borders on the unsettling. (One wonders if they have a secret archive of medical histories and questionable life choices.) A recession might affect their bottom line, naturally. People might, in a fit of economic prudence, attempt to not buy quite so many lottery tickets and oversized chocolate bars alongside their prescriptions. But CVS is more than just a place to pick up your antibiotics; it’s a convenience store, a MinuteClinic, and a burgeoning health insurance provider. This diversification, while arguably a sign of late-stage capitalism, does provide a degree of resilience. They’re not just selling you pills; they’re selling you the idea of wellness, and that, my friends, is a remarkably profitable business.

And so it is with these digital coins – Bitcoin, Ethereum, XRP – fallen now from the heights of a year past. A man might look at the charts, at the red staining the screen, and think to sell, to cut his losses. But sometimes, the most natural impulse is the least wise. To sell now, when the dust is thickest, might be to lock in a sorrow that needn’t be.

This Palantir, you understand, is not a simple firm. It is a most peculiar hybrid, a creature born of the cold logic of technology and the… let us say, robust appetites of those who concern themselves with matters of national security. They deal in information, naturally. But not the tidy, predictable sort. Oh no. This is information as a swirling vortex, a chaotic sea of data from which patterns, and, crucially, profits, may be dredged.

These smaller companies, they live and die by their pipelines, don’t they? A single molecule holds so much hope, so much potential for… well, for not disappearing. For Viking, that molecule is VK2735, a dual GLP-1/GIP agonist. A rather grand name for a substance aiming to address the commonplace afflictions of obesity and diabetes. It’s a field teeming with ambition, and a quiet desperation.